Archive for 2015

  • aside

    Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

    Isofol Medical AB today announced that the first dose cohort with Modufolin® as rescue therapy, after treatment with two cycles…

    by
  • aside

    Patent covering the use and pharmaceutical composition of Isofol’s lead Drug candidate, Modufolin®, allowed by United States Patent and Trademark Office

    Isofol Medical AB today announced that the United States Patent and Trademark Office has allowed Isofol’s patent No. 12/805,287, covering…

    by
  • aside

    First patient successfully treated with Modufolin® as a rescue therapy with high dose methotrexate (HDMTX) treatment in Osteosarcoma.

    Isofol Medical AB today announced that the first patient treated with Modufolin®, as rescue therapy, after treatment with two cycles…

    by
  • Stockholm Corporate Finance Life Science Day 2015

    Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day 2015 at Operaterrassen in Stockholm.…

    by
  • aside

    Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

    Gothenburg, Sweden, Cambridge UK, and Clinton NJ – February 2015 – Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in…

    by
  • aside

    A recently published study clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration.

    Isofol Medical AB announces publication of a study comparing the concentration of folate metabolites in tumor, mucosa, and plasma of…

    by